• sales@syndicatedanalytics.com
  • +1-213-316-7435

GCC HIV Drugs Market by Drug Class (Nucleoside Reverse Transcriptase Inhibitors, Multi-Class Combination Products, Protease Inhibitors, HIV Integrase Strand Transfer Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Entry Inhibitors — CCR5 Co-Receptor Antagonist and Fusion Inhibitors) and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others): Industry Analysis, Trends, Growth and Forecast 2022-2027



GCC HIV Drugs Market Overview:

The GCC HIV drugs market was worth US$ XX Billion in 2021, expanding at a CAGR of X% during 2016-2021. The market is projected to register a CAGR of X% during 2022-2027, reaching US$ XX Billion by 2027. The human immunodeficiency virus (HIV) is a retrovirus that attacks the immune system of the body by damaging the CD4 type of white blood cells (WBCs). HIV is transferred from one person to another through blood-to-blood and unprotected sexual contact, which, if left untreated can lead to acquired immunodeficiency syndrome (AIDS). Antiretroviral therapy (ART) is one of the most common methods of treating HIV, which uses HIV drugs to prevent the virus from multiplying and enhance the production of CD4 cells. Other types of available HIV drugs include Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Integrase Inhibitors, Fusion Inhibitors, and Ritonavir (RTV), which function by blocking the enzymes that HIV needs to make copies, thus reducing the overall viral load, controlling the growth of the virus, managing the symptoms, and preventing its transmission.

One of the primary factors driving the GCC HIV drugs market is the increasing prevalence of HIV across the region. This is further supported by the rising awareness regarding the disease causes, symptoms, and treatment options amongst consumers, which, in turn, is facilitating the need for the early detection of the disease, thereby enabling patients to adopt ART in the initial stage of the infection. Additionally, a well-established healthcare system, along with the advent of advanced treatments and modern medicines are acting as other growth-inducing factors. Besides this, the market is also positively influenced by a rise in the number of government initiatives to provide funds on the research and development (R&D) of innovative, safe, affordable, and efficient medication as an effective therapeutic solution. The increasing usage of generic drugs that are cost-effective and bio-equivalent to their branded counterparts, are projected to drive the market further toward growth.

GCC HIV Drugs Market Segment Insights:

The report has assessed the GCC HIV drugs market on the basis of drug class covering,  nucleoside reverse transcriptase inhibitors, multi-class combination products, protease inhibitors, HIV integrase strand transfer inhibitors, non-nucleoside reverse transcriptase inhibitors, entry inhibitors — CCR5 co-receptor antagonist and fusion inhibitors. The report has further examined the market based on distribution channel including, hospital pharmacies, retail pharmacies, online pharmacies and others. On a regional basis, the report examines the HIV drugs market in Saudi Arabia, United Arab Emirates, Qatar, Kuwait, Oman and Bahrain. An evaluation of the competitive landscape has also been provided with the details of the key players operating in the GCC HIV drugs market.
 

Highlights of the GCC HIV Drugs Market Report:

  • Historical and current scenario
  • Trends and developments
  • Impact of COVID-19
  • Market forecast
  • Price analysis and forecast
  • Porter’s five forces analysis
  • SWOT analysis
  • Value chain analysis

Key Market Segments:

The GCC HIV Drugs market has been analysed as followed:

Segmentation by Drug Class:

  • Nucleoside Reverse Transcriptase Inhibitors
  • Multi-Class Combination Products
  • Protease Inhibitors
  • HIV Integrase Strand Transfer Inhibitors
  • Non-Nucleoside Reverse Transcriptase Inhibitors 
  • Entry Inhibitors — CCR5 Co-Receptor Antagonist
  • Fusion Inhibitors

Segmentation by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Segmentation by Country:

  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Kuwait
  • Oman
  • Bahrain

Report Customisation:

The GCC HIV drugs market report can be customised as per your requirements. You can get in touch with our analyst, who will make sure that the report suits your research needs.

1 Introduction
    1.1    Research Objectives 
    1.2    Stakeholders
    1.3    Scope of the Report
    1.4    Assumptions and Limitations
2 Research Methodology 
    2.1    Data Collection
            2.1.1    Primary Sources
            2.1.2    Secondary Sources
    2.2    Market Size Estimation
            2.2.1    Bottom-Up Approach
            2.2.2    Top-Down Approach
    2.3    Data Validation
3 Executive Summary
4 Global HIV Drugs Market

    4.1    Historical Market Trend
    4.2    Market Segmentation by Region
    4.3    Market Outlook
5 GCC HIV Drugs Market
    5.1    Industry Overview 
    5.2    Key Industry Developments
    5.3    Market Trends
            5.3.1    Key Market Indicators
            5.3.2    Historical Market Trends
            5.3.3    Impact of COVID-19
            5.3.4    Market Outlook
6 GCC HIV Drugs Market Segmentation by Country
    6.1    Saudi Arabia  
            6.1.1    Historical Market Trends
            6.1.2    Market Outlook
    6.2    United Arab Emirates   
            6.2.1    Historical Market Trends
            6.2.2    Market Outlook
    6.3    Qatar 
            6.3.1    Historical Market Trends
            6.3.2    Market Outlook
    6.4    Kuwait 
            6.4.1    Historical Market Trends
            6.4.2    Market Outlook
    6.5    Oman  
            6.5.1    Historical Market Trends
            6.5.2    Market Outlook
    6.6    Bahrain  
            6.6.1    Historical Market Trends
            6.6.2    Market Outlook
7 GCC HIV Drugs Market Segmentation by Drug Class
    7.1    Nucleoside Reverse Transcriptase Inhibitors
            7.1.1    Historical Market Trends
            7.1.2    Market Outlook
    7.2    Multi-Class Combination Products
            7.2.1    Historical Market Trends
            7.2.2    Market Outlook
    7.3    Protease Inhibitors
             7.3.1    Historical Market Trends
             7.3.2    Market Outlook
    7.4    HIV Integrase Strand Transfer Inhibitors
             7.4.1    Historical Market Trends
             7.4.2    Market Outlook
    7.5    Non-Nucleoside Reverse Transcriptase Inhibitors 
            7.5.1    Historical Market Trends
            7.5.2    Market Outlook
    7.6    Entry Inhibitors — CCR5 Co-Receptor Antagonist
             7.6.1    Historical Market Trends
             7.6.2    Market Outlook
    7.7    Fusion Inhibitors
             7.7.1    Historical Market Trends
             7.7.2    Market Outlook
8 GCC HIV Drugs Market Segmentation by Distribution Channel
    8.1    Hospital Pharmacies
             8.1.1    Historical Market Trends
             8.1.2    Market Outlook
    8.2    Retail Pharmacies    
             8.2.1    Historical Market Trends
             8.2.2    Market Outlook
    8.3    Online Pharmacies
             8.3.1    Historical Market Trends
             8.3.2    Market Outlook
    8.4   Others    
            8.4.1    Historical Market Trends
            8.4.2    Market Outlook
9 GCC HIV Drugs Industry: Market Dynamics
    9.1    Overview
    9.2    Strengths
    9.3    Weaknesses 
    9.4    Opportunities
    9.5    Threats
10 GCC HIV Drugs Industry: Value Chain Analysis
    10.1   Overview
    10.2   Research and Development
    10.3   Raw Material Suppliers
    10.4   Inbound Logistics
    10.5   Production
    10.6   Marketing 
    10.7   Outbound Logistics
    10.8   Consumers 
11 GCC HIV Drugs Industry: Porter’s Five Forces Analysis
    11.1   Overview
    11.2   Threat of New Entrants
    11.3   Threat of Substitutes
    11.4   Bargaining Power of Buyers
    11.5   Bargaining Power of Suppliers
    11.6   Intensity of Rivalry
12 Competitive Landscape
    12.1   Market Structure
    12.2   Key Players 
    12.3   Key Success Factors 
13 Key Player Profiles
 
List of Figures

Figure 1: Global: HIV Drugs Market: Sales Value (in Billion US$), 2016-2021
Figure 2: Global: HIV Drugs Market: Segmentation by Region (in %), 2021
Figure 3: Global: HIV Drugs Market Outlook: Sales Value (in Billion US$), 2022-2027
Figure 4: GCC: HIV Drugs Market: Sales Value (in Billion US$), 2016-2021
Figure 5: GCC: HIV Drugs Market Outlook: Sales Value (in Billion US$), 2022-2027
Figure 6: GCC: HIV Drugs Market: Segmentation by Country (in %), 2021
Figure 7: GCC: HIV Drugs Market: Segmentation by Drug Class (in %), 2021
Figure 8: GCC: HIV Drugs Market: Segmentation by Distribution Channel (in %), 2021
Figure 9: Saudi Arabia: HIV Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 10: Saudi Arabia: HIV Drugs Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 11: United Arab Emirates: HIV Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 12: United Arab Emirates: HIV Drugs Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 13: Qatar: HIV Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 14: Qatar: HIV Drugs Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 15: Kuwait: HIV Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 16: Kuwait: HIV Drugs Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 17: Oman: HIV Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 18: Oman: HIV Drugs Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 19: Bahrain: HIV Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 20: Bahrain: HIV Drugs Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 21: GCC: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 22: GCC: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 23: GCC: HIV Drugs (Multi-Class Combination Products) Market: Sales Value (in Million US$), 2016 & 2021
Figure 24: GCC: HIV Drugs (Multi-Class Combination Products) Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 25: GCC: HIV Drugs (Protease Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 26: GCC: HIV Drugs (Protease Inhibitors) Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 27: GCC: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 28: GCC: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 29: GCC: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 30: GCC: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 31: GCC: HIV Drugs (Entry Inhibitors — CCR5 Co-Receptor Antagonist) Market: Sales Value (in Million US$), 2016 & 2021
Figure 32: GCC: HIV Drugs (Entry Inhibitors — CCR5 Co-Receptor Antagonist) Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 33: GCC: HIV Drugs (Fusion Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 34: GCC: HIV Drugs (Fusion Inhibitors) Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 35: GCC: HIV Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 36: GCC: HIV Drugs (Hospital Pharmacies) Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 37: GCC: HIV Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 38: GCC: HIV Drugs (Retail Pharmacies) Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 39: GCC: HIV Drugs (Online Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 40: GCC: HIV Drugs (Online Pharmacies) Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 41: GCC: HIV Drugs (Others) Market: Sales Value (in Million US$), 2016 & 2021
Figure 42: GCC: HIV Drugs (Others) Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 43: GCC: HIV Drugs Industry: Market Dynamics
Figure 44: GCC: HIV Drugs Industry: Value Chain Analysis
Figure 45: GCC: HIV Drugs Market: Porter’s Five Forces Analysis
 
List of Tables

Table 1: GCC: HIV Drugs Market: Key Industry Highlights, 2021 and 2027
Table 2: GCC: HIV Drugs Market Outlook: Segmentation by Country (in Million US$), 2022-2027
Table 3: GCC: HIV Drugs Market Outlook: Segmentation by Drug Class (in Million US$), 2022-2027
Table 4: GCC: HIV Drugs Market Outlook: Segmentation by Distribution Channel (in Million US$), 2022-2027
Table 5: GCC: HIV Drugs Market Structure
Table 6: GCC: HIV Drugs Market: Key Players

Special Prices


    Syndicated Analytics provides special pricing for:

  • Academic Institutes
  • Government Agencies
  • Nonprofit Organizations

  • For more information, feel free to contact us.





Related Reports

Saudi Arabia Health Insurance Market by Type (Individual and Group) by Service Provider (Public and Private): Industry Analysis, Trends, Growth and Forecast 2022-2027

The Saudi Arabia health insurance market was worth US$ XX Billion in 2021, expanding at a CAGR of X% during 2016-2021. Looking forward, the market is projected to grow at a CAGR of around X% during 2022-2027, reaching a value of US$ XX Billion by 2027.

Saudi Arabia In-Vitro Diagnostics (IVD) Market by Application (Infectious Diseases, Diabetes, Blood Test, Nephrology, Cardiology, Oncology, Autoimmune Diseases and Others) End-User (Hospital-Based Centres, Diagnostics Chains, Standalone Centres and Others): Industry Analysis, Trends, Growth and Forecast 2022-2027

The Saudi Arabia in-vitro diagnostics (ivd) market was worth US$ XX Billion in 2021, expanding at a CAGR of X% during 2016-2021. Looking forward, the market is projected to grow at a CAGR of around X% during 2022-2027, reaching a value of US$ XX Billion by 2027. 

GCC Intravenous Solutions Market by Type (Partial Parenteral Nutrition and Total Parenteral Nutrition) by Nutrients (Carbohydrates, Salts and Electrolytes, Minerals, Vitamins and Amino Acids): Industry Analysis, Trends, Growth and Forecast 2022-2027

The GCC intravenous solutions market was worth US$ XX Billion in 2021, expanding at a CAGR of X% during 2016-2021. Looking forward, the market is projected to grow at a CAGR of around X% during 2022-2027, reaching a value of US$ XX Billion by 2027.

UAE mHealth Market by Components, by Service Type, by Stakeholders and by Application: Industry Analysis, Trends, Growth and Forecast 2022-2027

The UAE mhealth market was worth US$ XX Billion in 2021, expanding at a CAGR of X% during 2016-2021. Looking forward, the market is projected to grow at a CAGR of around X% during 2022-2027, reaching a value of US$ XX Billion by 2027.

UAE In-Vitro Diagnostics Devices Market by Application (Infectious Diseases, Diabetes, Blood Test, Nephrology, Cardiology, Oncology, Autoimmune Diseases and Others) by End-User (Hospital-Based Centres, Diagnostics Chains, Standalone Centres and Others): Industry Analysis, Trends, Growth and Forecast 2022-2027

The UAE in vitro diagnostics devices market was worth US$ XX Billion in 2021, expanding at a CAGR of X% during 2016-2021. Looking forward, the market is projected to grow at a CAGR of around X% during 2022-2027, reaching a value of US$ XX Billion by 2027.